O ver the past decade, the treatment of Crohn's disease has changed remarkably, perhaps most notably with the introduction of antitumour necrosis factor monoclonal antibodies, the first of which was infliximab. Infliximab is approved for the treatment of moderate to severe luminal and fistulizing Crohn's disease that is refractory to standard therapy, which includes corticosteroid and immunosuppressive medications (1) . Although clinical trials have demonstrated the efficacy of infliximab for both induction (2, 3) and maintenance (4, 5) of remission, global availability remains restricted due to its cost (6) .
Crohn's disease, however, is associated with considerable economic costs. Early age of onset, high morbidity, slightly reduced to near normal life expectancy and higher prevalence in industrialized first-world nations (with an estimated prevalence of 234 per 100,000 persons in Canada [7] ) contribute to both high indirect costs (8) and direct costs (9) . Furthermore, the top 7% of patients with Crohn's disease are responsible for 50% of the total direct costs (10) , the majority of which are associated with hospitalizations and surgeries (11, 12) .
Several studies have demonstrated that infliximab decreases resource use (13) (14) (15) (16) (17) and, for some patients, infliximab may reduce health-related expenditures (13) . However, some analyses have suggested that infliximab therapy may actually increase total costs overall (17) , and perhaps more so in those who lose response to infliximab (18) . Additionally, practice patterns with regard to infliximab use have changed over the past decade, due in part to the acceptance of maintenance dosing, widespread adoption of immunosuppressive medications that enhance the efficacy and durability of infliximab therapy, and a shift toward outpatient care (19) .
Therefore, the objective of the present study was to examine the economic and resource use benefits of infliximab therapy for the first time in patients with Crohn's disease up to two years postinfusion therapy using patients who served as their own controls.
METHODS
A retrospective analysis of all patients with Crohn's disease treated with infliximab at the Zeidler Gastrointestinal Health Centre, University of Alberta Hospital (Edmonton, Alberta), between September 2000 and August 2007, was conducted. All patients with Crohn's disease who resided within the Capital Health Region for at least one year before and one year following the initiation of infliximab therapy were identified to ensure health care resource use was captured within the original artiCle ©2011 Pulsus Group Inc. All rights reserved DE Loomes, C Teshima, P Jacobs, R Fedorak. Health care resource use and costs for Crohn's disease before and after infliximab therapy. Can J Gastroenterol 2011;25(9):497-502.
BaCkGROunD: Infliximab therapy in patients with Crohn's disease decreases resource use; however, the overall impact on health-related expenditures is unclear, especially beyond one year of study. METHODS: A retrospective analysis of economic data one and two years before and after infliximab therapy was performed using patients who served as their own controls. Total health care resource use and direct health care costs were compared for patients with or without fistulae. RESuLTS: Patients with one (n=66) and two (n=39) years of economic data before and after infliximab treatment had their resource use and direct health care costs estimated. In the year following initiation of infliximab therapy, there were significant decreases in health care use, reflected in total hospital days (495 to . En général, les tendances des coûts de santé analysés pendant quatre années consécutives étaient similaires à ceux de l'analyse sur deux années consécutives. COnCLuSiOnS : La thérapie à l'infliximab chez les patients atteints de la maladie de Crohn assurait une diminution significative tant de l'utilisation des ressources que des coûts de santé, mais une augmentation du total des coûts directs de santé lorsqu'on ajoute le coût de l'infliximab. health region. Patients whose Crohn's disease responded to induction treatment with infliximab (loading doses at zero, two and six weeks) and who were followed for at least one year since the first infliximab infusion were included in the analysis. Clinical response to induction was defined according to the physician's global assessment 10 to 12 weeks after the first infliximab dose, as determined by the physician's documentation of significant and clinically relevant improvement in diarrhea, abdominal pain, extraintestinal symptoms and general well-being. This has previously been demonstrated to correlate closely with the Crohn's Disease Activity Index (20) . From 160 patients identified in the Zeidler database, 74 patients fulfilled the inclusion criteria. Sixtysix patients had complete costing data one year pre-and postinitiation of infliximab; 39 of these patients had complete costing data two years preceding and following infliximab therapy. All patients served as their own controls in the analysis.
In all cases, infliximab use was in accordance with the Canadian Association of Gastroenterology guidelines for infliximab treatment in Crohn's disease (1) . Patients who underwent previous treatment with other antitumour necrosis factor biological therapy for any indication, and who had a history of cancer with less than two years of documented disease-free state (other than resected cutaneous basal and squamous cell carcinoma or in situ cervical cancer) were excluded.
Retrospective analysis of patient charts was performed to gather baseline demographics. Disease subtype was not identified in five charts.
The primary end points were defined as direct resource use and health care costs before and after infliximab therapy. Health care resources and costs were divided into the following major categories: health care visit, endoscopy, radiology and therapeutic intervention; these categories were further subdivided into inpatient and outpatient services, and finally subdivided into various types of health care encounters. Some types of health care encounters were composed of multiple diagnoses or procedures. Nonsurgical management of inflammatory bowel disease (IBD)-related hospitalization was composed of management of IBD and of gastrointestinal obstruction. Minor surgeries were defined as less extensive esophageal, stomach and duodenal procedures, less extensive intestinal and rectal procedures, minor gastrointestinal procedures, abdominal laparoscopy, and anus and stomal procedures. Major surgeries were composed of major esophageal, stomach and duodenum procedures, major intestinal and rectal procedures, laparotomy, extensive gastrointestinal procedures, and gastrostomy and colostomy procedures.
Secondary outcomes were health care costs divided by the number of patients with Crohn's disease with fistulae or those without fistulae.
The inpatient costs in the current study, including direct patient care costs, administrative overhead, facility maintenance and other nonpatient care costs as measured by Case Mix Groups (CMG) and complexity modifier codes associated with each hospitalization, were derived from the Alberta Health and Wellness 2006 Annual Report, Health Costing In Alberta (21) . Doctors' fees were calculated using the provincial fee schedule (22) . Service categories were extrapolated from the Canadian Classification of Health Interventions codes that were included in each patient's hospital encounter information. There were no costs calculated for inpatient endoscopy and radiology because these were encompassed by the CMG code costs. Outpatient services included diagnostic tests, procedures and visits, but excluded costs of medications other than infliximab, as well as nonpatient care costs. Outpatient costs were extracted from the Ambulatory Care Classification System provincial costing database (21) , which contains direct costs for each procedure and visit type, and were added to the corresponding doctors' fees. The cost of infliximab was calculated using the median patient dose of 400 mg, and a supplier cost of CAD$3,152 per 400 mg (Canadian supplier cost at August 2010). All costs in the tables have been standardized to 2005 United States dollars (23, 24) . The total number of infliximab doses were determined by a retrospective review of each patient's infusion records.
Statistical analysis was performed using the statistical software programs Stata/MP 11 (StataCorp LP, USA). Primary and secondary outcome analyses were compared using a paired t test. Demographics were analyzed by descriptive methods, and P<0.05 was considered to be statistically significant.
RESuLTS

Patient demographics
The demographic characteristics of the patient population are summarized in Table 1 . In the analysis of 66 patients who had available economic data one year before and after infliximab, 62.1% of the study population were women and 93.9% were Caucasian. The mean (± SD) age at the time of the first infliximab infusion was 42.0±11.6 years. Length of time between diagnosis and first infusion of infliximab, and overall duration of Crohn's disease was 10.1±8.1 years and 15.8±8.7 years, respectively. The majority of patients had ileocecal (48.5%), colonic (36.4%) or ileal (15.2%) disease. The percentage of patients with fistulizing disease (47.0%) and nonfistulizing disease (45.5%) were comparable (note: in five records, it was not possible to confirm the presence or absence of fistulizing disease). Patients analyzed according to either one year or two years before and after infliximab were similar in all characteristics, with the exception of the mean percentage of patients on infliximab at the end of the study period (66.7% versus 56.4%), and the mean number of infliximab infusions per year (7.4±1.4 infusions versus 5.7±2.1 infusions). In the subgroup analysis of patients with or without fistulizing disease one year before and after infliximab, there was no difference in infliximab use (64.5% and 63.3%, respectively).
Health care resource use before and after infliximab use Total health care resource use one year and two years before and after infliximab therapy were compared ( 
Comparison of health care costs before and after infliximab therapy
Health care costs per patient one year and two years before and after infliximab therapy were compared (Table 3) . One-year analysis: There was a reduction in total combined inpatient and outpatient costs (−$ 
DiSCuSSiOn
Infliximab is a mainstay of therapy for moderate to severe Crohn's disease due to its superior efficacy in the treatment of luminal (4) and fistulizing (5) disease over traditional therapies such as corticosteroids and immunosuppressive medications. However, despite this widespread use, the overall impact on health-related expenditures is unclear.
The results of the present study demonstrated a reduction in inpatient resource use and costs with infliximab therapy. This reduction may extend into the second year of treatment, despite an overall decrease in infliximab use over this time. The present analysis suggests, as do other similar studies (13, 25) , that this reduction in inpatient costs is largely driven by a decrease in hospitalizations, colonoscopies and surgeries. When the cost of infliximab is factored into the analysis, there was a net increase in overall direct costs, similar to the findings of Saro et al (17) . However, in countries with a higher cost structure, such as the United States, a combined reduction of inpatient and outpatient costs by almost 50% after two years of treatment may very well translate into an overall cost savings with infliximab therapy.
The magnitude of health care cost savings in patients with fistulizing disease may be greater than for those without fistulizing disease. A greater decrease in hospitalizations and surgical interventions in patients with fistulizing disease has been previously suggested (15) . In the present analysis, the decrease in combined inpatient and outpatient costs was only significant for patients with fistulizing disease, although combined costs did trend downward in the nonfistulizing subgroup. Both subgroups of patients showed similar downward trends in major surgeries. A recent study by Taxonera et al (26) did not demonstrate a difference in hospitalizations or surgeries between fistulizing and nonfistulizing subgroups. 
Data presented as $
It is recognized that the present study was limited by its retrospective design and the lack of a traditional control group. However, given that the population studied was considered to be a representative sample and that infliximab is now of proven benefit for patients with Crohn's disease, using a control group would be neither ethical nor reasonable. The absence of outpatient drug costing data potentially limited some additional savings with infliximab. Although infliximab is recognized to be corticosteroid sparing in approximately one-third of patients (4), overall, the cost of corticosteroids are relatively low compared with the other direct costs involved. Infliximab use is not expected to result in cost savings of immunosuppressives as evidenced by the Study of Biologic and Immunomodulator Naive Pateints in Crohn's disease (SONIC) trial (27) .
The current study only included responders to infliximab in the analysis because its objective was to examine patient costs before and after therapy. Patients excluded from the present analysis comprised a heterogenous group of patients who did not tolerate infliximab infusions or did not respond to induction therapy. The economic implications of including patients with a lack of response to infliximab or those that do not tolerate infliximab will lead to higher associated economic costs.
Perhaps the greatest limitation of the majority of economic studies to date is the lack of indirect costing data. Concessions made in career choices, disability compensation, early retirement and unemployment are all indirect costs to society that are difficult to quantify, but have been estimated to be responsible for 68% of overall health care expenditures (8). Crohn's disease is associated with a significantly decreased quality of life (28) , and induction and maintenance of remission has been demonstrated to increase employment and normalize quality of life (16, 29) . Thus, the present analysis likely underestimated the true financial burden of Crohn's disease. Additional studies regarding the indirect costs of Crohn's disease are needed to elucidate the impact of infliximab on overall cost effectiveness. 
